{
    "clinical_study": {
        "@rank": "31595", 
        "arm_group": [
            {
                "arm_group_label": "Levofloxacin-triple therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Lansoprazole  (Proton Pump Inhibitor), Levofloxacin, Amoxicillin"
            }, 
            {
                "arm_group_label": "Levofloxacin-quadruple therapy", 
                "arm_group_type": "Experimental", 
                "description": "Lansoprazole (Proton Pump Inhibitor),Bismuth, Levofloxacin, Amoxicillin"
            }
        ], 
        "brief_summary": {
            "textblock": "To examine and compare the efficacy of 2 week Levofloxacin-containing therapies with and\n      without Bismuth for H.pylori treatment."
        }, 
        "brief_title": "Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Functional Dyspepsia", 
            "Peptic Ulcer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dyspepsia", 
                "Peptic Ulcer", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "The success rate of the standard triple therapy for H. pylori infection is decreasing\n      recently.Fluoroquinolone has been proposed to replace clarithromycin as an alternative in\n      the treatment. However prevalence of H.pylori resistance to Levofloxacin has increased\n      rapidly in our area. The purpose of this study is to observe the efficacy of 14 day\n      Levofloxacin triple therapy-based, bismuth-containing quadruple therapy for H.pylori\n      treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients who presented with upper gastrointestinal symptoms and endoscopically proven\n             H.pylori-positive functional dyspepsia and scarred peptic ulcer\n\n        Exclusion Criteria:\n\n          -  patients with peptic ulcer, previous H.pylori eradication therapy, previous gastric\n             surgery, pregnancy, lactation, major systemic diseases, receipt of anti-secretory\n             therapy, antibiotics or bismuth in the preceding 4 weeks, or allergy to any one of\n             the medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "161", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667718", 
            "org_study_id": "rjkls2012011"
        }, 
        "intervention": [
            {
                "arm_group_label": "Levofloxacin-quadruple therapy", 
                "description": "Bismuth 220mg b.i.d for 2 weeks", 
                "intervention_name": "Bismuth", 
                "intervention_type": "Drug", 
                "other_name": "Bismuth potassium citrate"
            }, 
            {
                "arm_group_label": [
                    "Levofloxacin-triple therapy", 
                    "Levofloxacin-quadruple therapy"
                ], 
                "description": "Lansoprazole 30 mg b.i.d.for 2 weeks", 
                "intervention_name": "Lansoprazole", 
                "intervention_type": "Drug", 
                "other_name": "Proton Pump Inhibitor"
            }, 
            {
                "arm_group_label": [
                    "Levofloxacin-triple therapy", 
                    "Levofloxacin-quadruple therapy"
                ], 
                "description": "Levo\ufb02oxacin 0.5 q.d. for 2 weeks", 
                "intervention_name": "Levo\ufb02oxacin", 
                "intervention_type": "Drug", 
                "other_name": "Levo\ufb02oxacin"
            }, 
            {
                "arm_group_label": [
                    "Levofloxacin-triple therapy", 
                    "Levofloxacin-quadruple therapy"
                ], 
                "description": "Amoxicillin 1 g b.i.d. for 2 weeks", 
                "intervention_name": "Amoxicillin", 
                "intervention_type": "Drug", 
                "other_name": "Amoxicillin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amoxicillin", 
                "Ofloxacin", 
                "Lansoprazole", 
                "Bismuth", 
                "Potassium Citrate", 
                "Proton Pump Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "eradication", 
            "helicobacter pylori", 
            "bismuth"
        ], 
        "lastchanged_date": "December 12, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200127"
                }, 
                "name": "Shanghai Jiao-Tong University School of Medicine Renji Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Levofloxacin-containing Therapy for Helicobacter Pylori Treatment", 
        "overall_official": {
            "affiliation": "Shanghai Jiao-Tong University School of Medicine Renji Hospital", 
            "last_name": "Hong Lu", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Renji Hospital, Shanghai Jiaotong University, School of Medicine:China", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "eradication rate of Helicobacter pylori", 
            "safety_issue": "Yes", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667718"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Jiao Tong University School of Medicine", 
            "investigator_full_name": "Dr. HONG LU", 
            "investigator_title": "Professor of  GI Division", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Jiao Tong University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}